Virus-Immunotherapy cocktail takes on tough GI cancers
NCT ID NCT07280377
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial is testing a combination of pelareorep (a reovirus) and atezolizumab (an immunotherapy) along with standard chemotherapies in people with advanced anal or pancreatic cancers. The study aims to find safe doses, look for biomarkers that predict response, and measure early signs of tumor shrinkage or disease control. About 122 participants are enrolled across five groups, each receiving different drug combinations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pelareorep and atezolizumab (plus chemotherapy drugs like gemcitabine, nab-paclitaxel, trifluridine/tipiracil, or mFOLFIRINOX)
What this could lead to
If successful, this could point toward new treatment options for advanced gastrointestinal cancers that are hard to treat.
What could go wrong
This is an early phase 1/2 study with a small number of participants, so results may not confirm effectiveness. The combination therapies also carry risks of side effects from both the drugs and chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE PANCREATIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asklepios Kliniken Hamburg GmbH
Hamburg, Free and Hanseatic City of Hamburg, 22763, Germany
-
Caritasklinikum Saarbrücken St. Theresia
Saarbrücken, Saarland, 66113, Germany
-
Charité Universitätsklinikum Berlin
Berlin, State of Berlin, 13353, Germany
-
Gemeinschaftspraxis Dr. Med Bernhard Heinreich
Augsburg, Bavaria, 86150, Germany
-
Hämatologisch-Onkologische Praxis Eppendorf
Hamburg, Free and Hanseatic City of Hamburg, 20249, Germany
-
Klinikum Chemnitz gGmbH
Chemnitz, Saxony, 09116, Germany
-
Klinikum der Universität München
München, Bavaria, 81377, Germany
-
Krankenhaus Nordwest
Frankfurt am Main, Hesse, 60488, Germany
-
Nationales Centrum für Tumorerkrankungen Heidelberg
Heidelberg, Baden-Wurttemberg, 69120, Germany
-
SLK-Kliniken Heilbronn GmbH
Heilbronn, Baden-Wurttemberg, 74078, Germany
-
St. Josef-Hospìtal, Bochum
Bochum, North Rhine-Westphalia, 44791, Germany
-
Universität Leipzig
Leipzig, Saxony, 04103, Germany
-
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, 72076, Germany
-
Universitätsklinikum Ulm
Ulm, Baden-Wurttemberg, 89081, Germany
-
Universitätsmedizin Mainz
Mainz, Rhineland-Palatinate, 55131, Germany